An expert panel, meeting in an emergency session last week, urged the U.S. Food and Drug Administration to lift a hold it had placed on three gene therapy trials after a patient treated with gene therapy in France developed cancer. The panel made the recommendation after concluding that the cancer was almost certainly caused by the gene therapy.